New drug combo aims to cut nausea in weight loss treatments
NCT ID NCT07411560
First seen Feb 20, 2026 · Last updated Jun 20, 2026 · Updated 16 times
Summary
This early-stage trial is testing whether combining two experimental weight loss drugs—cagrilintide and a GIP receptor agonist—causes fewer stomach side effects like nausea and vomiting compared to taking cagrilintide alone. About 100 women who are overweight or obese will receive both drugs in one period and cagrilintide plus a placebo in another. The study lasts about 4.5 months and focuses on safety and tolerability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Parexel Research Unit
RECRUITINGHarrow, Middlesex, HA1 3UJ, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cagrilintide and NNC0480-0389 (a GIP receptor agonist)
What this could lead to
If successful, this could lead to a more tolerable weight loss drug combination with fewer stomach side effects.
What could go wrong
This is a very early Phase 1 trial with only 100 women, so results may not apply to everyone. The main goal is safety and tolerability, not weight loss, so it's too soon to know if the combo will actually help people lose weight.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.